Skip to content

Trial Summary

The goal of this randomized treatment de-escalation study is to formally compare outcomes in HPV related oropharyngeal cancer tumors treated with a primary radiotherapy versus a primary surgical approach, to provide a high level of evidence to guide the selection of treatment options for a subsequent phase III trial.

Acronym:

ORATOR II

ACTRN/NCT /ethics:

NCT03210103

Scientific title:

A Randomized Trial of Treatment De-Escalation for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs. Trans-Oral Surgery (ORATOR II)

Sponsor / Cooperative group:

London Regional Cancer Program

Trial & Patient Characteristics

Cancer TypeHead and Neck
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexBoth
Tumour Stream Oropharyngeal Squamous Cell Carcinoma
Cancer StageAll stages
Anticipated Start Date2018-01-26
Anticipated End Date2028-08-15

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorDr Surendranath Krishnan
Recruitment StatusRecruiting